These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 19581184)

  • 1. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Vectibix (panitumumab)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):175-6. PubMed ID: 19581184
    [No Abstract]   [Full Text] [Related]  

  • 2. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Ratiograstim (biocompatible filgrastim)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):177-8. PubMed ID: 19581185
    [No Abstract]   [Full Text] [Related]  

  • 3. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
    Pikó B;
    Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 5. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 6. [Utilization of antineoplastic agents in Sweden and Europe].
    Wilking N; Jönsson B; Björn W
    Lakartidningen; 2010 Apr 21-27; 107(16):1075-80. PubMed ID: 20476705
    [No Abstract]   [Full Text] [Related]  

  • 7. Panitumumab (Vectibix) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
    [No Abstract]   [Full Text] [Related]  

  • 8. Norway backs downs over plan to exclude anticancer drugs from coverage.
    Hansen A
    BMJ; 2013 Mar; 346():f1707. PubMed ID: 23491458
    [No Abstract]   [Full Text] [Related]  

  • 9. [New oncolytic agents and immunomodulators and their application].
    Lange R; Maring JG
    Ned Tijdschr Geneeskd; 2005 Oct; 149(40):2256-7; author reply 2257-8. PubMed ID: 16235808
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in oncology. Panitumumab and combination chemotherapy in first- and second-line therapy for colorectal cancer.
    Chan E
    Clin Adv Hematol Oncol; 2010 Jan; 8(1):37-9. PubMed ID: 20351681
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter to the editor.
    Muhonen T
    J Med Econ; 2014 Jun; 17(6):442. PubMed ID: 24724704
    [No Abstract]   [Full Text] [Related]  

  • 12. [Assessment of annual health insurance reimbursement for oncology drugs in Hungary].
    Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
    Magy Onkol; 2010 Dec; 54(4):283-8. PubMed ID: 21163758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter to the editor: author response.
    Rautenberg T
    J Med Econ; 2014 Jun; 17(6):443. PubMed ID: 24724705
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.
    Wainberg Z; Hecht JR
    Clin Colorectal Cancer; 2006 Jan; 5(5):363-7. PubMed ID: 16512997
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
    Giusti RM; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Panitumumab].
    Musch A
    Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hype over herceptin.
    Fitzpatrick J
    Nurs N Z; 2009 Mar; 15(2):4-5. PubMed ID: 19554708
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges and opportunities for use of cost-effectiveness analysis.
    Yabroff KR; Schrag D
    J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
    [No Abstract]   [Full Text] [Related]  

  • 20. Panitumumab: new drug. Metastatic colorectal cancer: don't make things worse!
    Prescrire Int; 2009 Aug; 18(102):157. PubMed ID: 19743571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.